Risk of Thrombocytopenia by SSRIs or SNRIs in Patients With Depression Based on MID‐NET: A Cohort Study in Japan

Documenti analoghi

• PMDA Perspective on RWD/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage
  di: Kazuhiro Kajiyama, et al.
  Pubblicazione: (2024)
• New Function for Safety Signal Monitoring in MID‐NET®: The Case of an Anti‐COVID‐19 Drug
  di: Yusuke Okada, et al.
  Pubblicazione: (2025)
• Risk of artery dissection during systemic exposure to vascular endothelial growth factor pathway inhibitors
  di: Jun Okui, et al.
  Pubblicazione: (2024)
• Inter‐rater reliability study of the Japanese version of the diagnostic clinical interview for drug withdrawal post SSRIs or SNRIs (DID‐W1‐J)
  di: Tomoyuki Nakamura, et al.
  Pubblicazione: (2025)
• Asymmetric simple exclusion process with tree-like network branches
  di: Ishiguro, Yuki, et al.
  Pubblicazione: (2026)